Innovate will acquire all outstanding capital stock of RDD in exchange for a combination of common and preferred shares.
After the merger, the combined entity will be renamed 9 Meters Biopharma. Current RDD CEO John Temperato will become head of the new venture. Mr. Temperato notably helped build out Salix Pharmaceuticals before its acquisition by Bausch Health, then known as Valeant Pharmaceuticals.
More articles on surgery centers:
Proposal submitted for $10.4M Tennessee surgery center project
49 ASC transactions through the first 3 quarters of 2019
California practices merge, plan to open surgery center
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.